| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 3,103 | 4,004 | ||
| Accounts receivable | 3 | 3 | ||
| Prepaid expenses, deposits, and other current assets | 1,085 | 1,481 | ||
| Total current assets | 4,191 | 5,488 | ||
| Fixed assets, net | 81 | 100 | ||
| Operating lease right-of-use assets | 2,131 | 2,256 | ||
| Equity method investment - at fair value | 31,615 | 35,998 | ||
| Other assets | 51 | 51 | ||
| Total assets | 38,069 | 43,893 | ||
| Accounts payable | 342 | 387 | ||
| Accrued expenses and other current liabilities | 2,660 | 2,777 | ||
| Operating lease liabilities, current portion | 557 | 542 | ||
| Senior secured convertible notes - at fair value | 6,900 | 6,800 | ||
| Total current liabilities | 10,459 | 10,506 | ||
| Operating lease liabilities, less current portion | 1,823 | 1,968 | ||
| Total liabilities | 12,282 | 12,474 | ||
| Preferred stock, 0.001 par value. authorized, 20,000,000 shares series c convertible preferred stock, stated value 1,058 at september 30, 2025, and issued and outstanding of 3,081 shares at september 30, 2025 and no shares issued and outstanding as of december 31, 2024 | 3,260 | 3,260 | ||
| Preferred stock, value-Series BConvertible Preferred Stock | 3,575 | 3,487 | ||
| Preferred stock, value-Series CConvertible Preferred Stock | 20,492 | 21,083 | ||
| Common stock, 0.001 par value. authorized, 250,000,000 shares (note 13) 23,053,498 and 11,198,977 shares outstanding as of september 30, 2025 and december 31, 2024, respectively | 23 | 20 | ||
| Additional paid-in capital | 265,331 | 263,515 | ||
| Accumulated deficit | -256,901 | -250,575 | ||
| Total pavmed inc. stockholders equity (deficit) | 32,520 | 37,530 | ||
| Noncontrolling interests | -9,993 | -9,371 | ||
| Total stockholders equity (deficit) | 22,527 | 28,159 | ||
| Total liabilities, mezzanine equity and stockholders equity (deficit) | 38,069 | 43,893 | ||
PAVmed Inc. (PAVM)
PAVmed Inc. (PAVM)